Capecitabine in Inhibition of Recurrence and Metastasis after Liver Cancer Resection in Nude Mice

周俭,汤钊猷,吴志全,樊嘉,纪元,王鲁,薛琼,鲍卫华
DOI: https://doi.org/10.3760/j:issn:0529-5815.2001.03.009
2001-01-01
Abstract:Objective To evaluate the inhibition effect of capecitabine [a new prodrug of 5-fluorouracil which is dependent on platelet-derived endothelial cell growth factor (PD-ECGF)], on recurrence and metastasis after liver cancer resection in LCI-D20, a nude mice model with highly metastatic human liver cancer. Methods The protein level of PD-ECGF was determined by using immunohistochemical method in 18 liver cancer samples and 18 lung metastasis samples of LCI-D20. The liver tumors were radically removed in 24 LCI-D20 nude mice on day 10 after their orthotopic implanting. Capecitabine, 5-fluorouracil, and arabic gum (control) via oral administration were used on day 3 after their removal. All treatment lasted 3 weeks. The tumor size was calculated by using the formula: V=a×b2×0.5. The AFP levels in the plasma of the nude mice were detected by radioimmunoassay. Lung metastasis was evaluated by HE staining in lung samples. Results PD-ECGFs were expressed in all 18 liver cancer and 18 lung metastasis samples. After the intervention of capecitabine, the size of recurrent intrahepatic tumor [(168±206)mm3] was smaller than that of the control [(3 162±690)mm3]. The AFP level [(107±90)ng/ml] was also significantly lower than that of the control [(1 519±807)ng/ml] (P<0.05). The rate of intrahepatic recurrence and lung metastasis decreased significantly (P<0.05). However, no difference was noted in the above characteristics between the 5-fluorouracil group and the control group. Conclusion Capecitabine may inhibit the recurrence and metastasis of highly metastatic liver cancer after its resection.
What problem does this paper attempt to address?